New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis

PHASE3CompletedINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

June 30, 2007

Conditions
Ulcerative Colitis
Interventions
DRUG

5 ASA, enemas, suppositories, corticosteroids

Trial Locations (66)

10128

New York

12180

Upstate Gastroenterology Associates, PC, Troy

13210

VA Medical Center, Syracuse

20636

Mid Atlantic Medical Research Centers, Hollywood

21208

Woodholme Gastroenterology Associates, PA, Baltimore

21215

Sinai Medical Office Building, Baltimore

23320

Gastroenterology Associates of Tidewater, Chesapeake

27262

Bethany Medical Center, High Point

27265

LeBauer Research Associates, PA, Greensboro

27804

Boice-Willis Clinic, Rocky Mount

29414

Charleston Gastroenterology Specialists, LLC, Charleston

29681

Hillcrest Clinical Research LLC, Simpsonville

30033

The Atlanta Center for Gastroenterology, Decatur

30308

Gary Richter, M.D., Atlanta

31201

Gastroenterology Associates of Central Georgia, Macon

32168

United Medical Research, New Smyrna Beach

33013

Medical Research Unlimited, Hialeah

33021

Mark Lamet, M.D., Hollywood

Southern Clinical Research Consultants, Hollywood

33162

Venture Research Institute, LLC, North Miami Beach

33401

Metabolic Research Institute, Inc., West Palm Beach

34233

Lovelace Scientific Resources, Sarasota

34239

Advent Clinical Research, Sarasota

34609

Clinical Research of Tampa Bay, Inc., Spring Hill

34684

Advanced Gastroenterology Associates, Palm Harbor

35209

Birmingham Gastroenterology Associates, Birmingham

36608

Spring Memorial Hospital, Mobile

37205

Nashville Medical Research Institute, Nashville

37660

Gastroenterology Associates, Kingsport

37909

Gastrointestinal Associates, Knoxville

38210

Memphis Gastroenterology Group, Memphis

40202

University of Louisville, Louisville

44484

Avamar Center for Gastroenterology, Inc., Warren

45219

Consultants for Clinical Research, Inc., Cincinnati

48047

Clinical Research Institute of Michigan, LLC, Chesterfield

50702

Covenent Clinic, Waterloo

60005

Northwest Gastroenterologists S.C., Arlington Heights

60452

University Digestive Health Center, Oak Forest

63128

St. Louis Center for Clinical Research, St Louis

65265

Center for Digestive & Liver Diseases, Mexico

66606

Digestive Health Center, Topeka

67131

Kansas City

70809

Digestive Health Center of Louisiana, Baton Rouge

72205

Little Rock Diagnostic Clinic, Little Rock

77030

Clinical Trial Network, Houston

77034

NationsMed Clinical Research, Houston

77090

Houston Digestive Disease Clinic, Houston

90211

Lovelace Scientific Resources, Beverly Hills

90822

Long Beach VA Medical Center, Long Beach

91345

Facey Medical Group, Mission Hills

92653

Therapeutic Research Institute of Orange County, Laguna Hills

92704

Lovelace Scientific Resources, Santa Ana

92801

Advanced Clinical Research Institute, Anaheim

92840

Digestive Liver Disease Specialists, Medical Group, Garden Grove

92868

Community Clinical Trials, Orange

93108

Santa Barbara Clinical Research, Santa Barbara

94117

Rider Research Group, San Francisco

94901

John Jolley, M.D., San Rafael

98133

Seattle Gastroenterology Associates, Seattle

98405

Tacoma Digestive Disease Research Center, Tacoma

99204

Eastern Washington Clinical Research Center, Spokane

Spokane Digestive Disease Center Research, Spokane

06010

Connecticut Gastroenterology Institute, Bristol

06905

Stamford Therapeutic Consortium, Stamford

07202

Central Jersey Primary Care Inc., Elizabeth

07712

Ocean City

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT00269438 - New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter